PTI stock closed up 5% on December 4, 2019, on positive Cantor Fitzgerald comments.

Analyst Kristen Kluska of Cantor Fitzgerald assumed coverage of Proteostasis Therapeutics (PTI) stock with an Overweight rating and a price target of $8. The stock is now set up for success, Kluska tells investors in a research note.

PTI stock closed strong in after-hours trading on December 4, 2019.

PTI stock closed near the HOD in AH trading on December 4, 2019.

Back on November 6, 2019, Piper Jaffray analyst Edward Tenthoff noted that Proteostasis said it has completed enrollment of the Phase 2 study of 60 f508del cystic fibrosis patients ahead of schedule and is now guiding to top-line data by year-end 2019, which is ahead of the prior expectation of the first quarter of 2020. If it generates positive data for the triple combo of amplifier PTI-428 with CFTR corrector PTI-801 and potentiator PTI-808, Proteostasis could initiate a Phase 3 trial next year, said Tenthoff, who has an Overweight rating and $4 price target on PTI stock.

finviz dynamic chart for  PTI
Proteostasis Therapeutics News From Google